AbCellera Biologics Inc. Common Shares (ABCL)
AbCellera Biologics Inc. is a biotechnology company focused on discovering and developing monoclonal antibodies. Using its人工智能-powered platform, the company analyzes natural immune responses to identify potential therapeutic candidates for various diseases, including infectious diseases, cancer, and inflammatory conditions. Founded in 2012 and based in Canada, AbCellera collaborates with pharmaceutical and biotech partners to advance its antibody discovery pipeline.
Company News
Prelude Therapeutics reported a Q2 2025 net loss of $31.2 million, reduced operating expenses, and focused on its oral SMARCA2 degrader program while maintaining cash reserves to fund operations into Q2 2026.
The antibody discovery market is projected to grow at a 10% CAGR by 2032, driven by increasing chronic disease incidence, biologics adoption, and technological advancements in drug development.
AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 12.50% and 11.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Benchmark analyst Robert Wasserman reiterated a Buy rating on AbCellera Biologics Inc. (NASDAQ: ABCL), lowering the price target to $12 on reduced valuations for other drug discovery stocks. AbCellera's shares have declined recently following peaks during the pandemic-fueled boom as royalties from sales of R&D partner Eli Lilly And Company's (NYSE: LLY) COVID-19 antibody therapeutics have disappeared, the analyst notes. The analyst added that beyond the two already marketed COVID-19 antibodies partnered with Eli Lilly, AbCellera has seven molecules in the clinical pipeline. The analyst noted that the long-term prospects ...Full story available on Benzinga.com